Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

A therapy PUSh for GBM

Nature Cancer volume 2, pages 876–878 (2021)Cite this article

Subjects

Pseudouridine is the most abundant RNA modification, but its biological role remains poorly understood. A study now finds dysregulated pseudouridine synthase PUS7 in glioblastoma and demonstrates that pharmacological inhibition of PUS7 leads to reduced tumorigenesis, which underpins the therapeutic potential of targeting epitranscriptomic regulators in cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Pharmacological or genetic modulation of PUS7’s activity prevents GBM tumorigenesis.

References

  1. Cohn, W. E. & Volkin, E. Nature 167, 483–484 (1951).

    Article  CAS  Google Scholar 

  2. Spenkuch, F., Motorin, Y. & Helm, M. RNA Biol. 11, 1540–1554 (2014).

    Article  PubMed  Google Scholar 

  3. Nombela, P., Miguel-Lopez, B. & Blanco, S. Mol. Cancer 20, 18 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cui, Q. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-0238-0 (2021).

  5. Lathia, J. D. et al. Genes Dev. 29, 1203–1217 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Marine, J. C., Dawson, S. J. & Dawson, M. A. Nat. Rev. Cancer 20, 743–756 (2020).

    Article  CAS  PubMed  Google Scholar 

  7. Heiss, N. S. et al. Nat. Genet. 19, 32–38 (1998).

    Article  CAS  PubMed  Google Scholar 

  8. Guzzi, N. et al. Cell 173, 1204–1216.e1226 (2018).

    Article  CAS  PubMed  Google Scholar 

  9. Krstulja, A. et al. Macromol. Biosci. 17, 1700250 (2017).

    Article  Google Scholar 

  10. Zeleznik, O. A. et al. Cancer Res. 80, 1357–1367 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sridharan, G., Ramani, P., Patankar, S. & Vijayaraghavan, R. J. Oral Pathol. Med. 48, 299–306 (2019).

    Article  CAS  PubMed  Google Scholar 

  12. Su, R. et al. Cell 172, 90–105.e123 (2018).

    Article  CAS  PubMed  Google Scholar 

  13. Yankova, E. et al. Nature 593, 597–601 (2021).

    Article  CAS  PubMed  Google Scholar 

  14. Cui, Q. et al. Cell Rep. 18, 2622–2634 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas–University of Salamanca, Salamanca, Spain

    Virginia Morón-Calvente & Sandra Blanco

  2. Instituto de Investigación Biomédica de Salamanca, Hospital Universitario de Salamanca, Salamanca, Spain

    Virginia Morón-Calvente & Sandra Blanco

Authors
  1. Virginia Morón-Calvente
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra Blanco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandra Blanco.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morón-Calvente, V., Blanco, S. A therapy PUSh for GBM. Nat Cancer 2, 876–878 (2021). https://doi.org/10.1038/s43018-021-00255-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-021-00255-z

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer